A prospective study on efficacy of nicorandil and isosorbide mononitrate in coronary artery disease

Abstract

Background: The aim of this prospective study was to assess the efficacy of Nicorandil (NR) and Isosorbide Mononitrate (ISMN) in coronary artery disease (CAD). Nicorandil strengthens CAD treatment by inhibiting cardiac fatty acid oxidation, easing aggravation and improving heart function, which is critical for preventing heart failure and other significant consequences. Methods: 110 patients with CAD were selected as research subjects and randomly assigned to two groups: observational (Group O) and control (Group C), with 55 patients in each. The control group was given traditional CAD treatment, whereas the observational group received NR and ISMN in addition to conventional treatment. The blood pressure, CRP, left ventricular ejection fraction (LVEF), troponin T, and ST-segment levels of two groups were assessed and compared at baseline, as well as after the second and fourth months, respectively. Results: This study found significant differences (P<0.05) between the observational and control groups in terms of BP, CRP, troponin T, and ST segment levels after the second and fourth months, whereas LVEF rose significantly (P<0.05) using one-way ANOVA. Similarly, an independent t-test was used to assess significant improvements in each group. Conclusions: The addition of Nicorandil and Isosorbide Mononitrate to a standard CAD regimen was found to have an important association with LVEF and inflammatory mediators, which can significantly improve cardiac functions while also preventing other cardiovascular complications in patients with coronary artery disease.